Tag: Drug Pricing

Xconomy: Spark CEO Marrazzo on Gene Therapy Pricing & Paving the Way for the Field | Xconomy

Xconomy: Spark CEO Marrazzo on Gene Therapy Pricing & Paving the Way for the Field | Xconomy

In early January, the company announced Luxturna’s price and a deal with New England insurer Harvard Pilgrim Health Care on a plan that includes rebates tied to the drug’s durability. In a departure from typical practices, Spark will sell the therapy directly to Harvard Pilgrim, not the medical center doing the procedure, which avoids potential […]

Prices and Competition to Shape the Year Ahead | Pharmaceutical Executive

Prices and Competition to Shape the Year Ahead | Pharmaceutical Executive

The pharmaceutical industry faces a tumultuous year in Washington, as policymakers continue to press for curbs on too-high drug prices, and tax and budget reforms may threaten resources and initiatives for the FDA, the National Institutes of Health, and public health programs. Inaction by Congress and the White House will prompt more states to propose […]

Trump is right: Negotiate for lower drug prices | IndyStar

Trump is right: Negotiate for lower drug prices | IndyStar

All Hoosiers have seen the headlines about drug price increases, and too many of us see the struggle first-hand. A vial of insulin can cost a person with diabetes 10 times as much as it did in the late 1990s.The price of an EpiPen has risen 450%. Some new treatments for cancer and other diseases […]

Spark Should Spark a Pricing Trend | Bloomberg Gadfly

Spark Should Spark a Pricing Trend | Bloomberg Gadfly

Spark Therapeutics Inc. announced lower-than-expected pricing and a performance-based discount program Wednesday for its recently approved gene therapy Luxturna, a one-time treatment that helps restore sight for patients with a rare genetic condition. It’s a risky move for the company; there are very few such patients, and the price of every treatment matters a great deal.But […]

The gene therapy pricing debate gets real as Spark sets $850,000 charge for its pioneering drug | Endpoints News

The gene therapy pricing debate gets real as Spark sets $850,000 charge for its pioneering drug | Endpoints News

Years of debate, speculation and analysis have boiled down to this: Spark $ONCE Therapeutics has set an $850,000 wholesale acquisition cost for the US’s first gene therapy — $425,000 per eye damaged by an RPE65 gene mutation. Set to roll out in a matter of weeks, the WAC price for Luxturna falls toward the higher […]

Pharma, under attack for drug prices, started an industry war | The Washington Post

Pharma, under attack for drug prices, started an industry war | The Washington Post

It’s not easy to get Americans mad at a behind-the-scenes industry they’ve barely even heard of, but pharmaceutical companies have spent most of this year trying. “Who decides what you pay for your medicines? Not who you might think,” a concerned woman’s voice says in a radio spot airing in the District last month. “More […]

From $50, to $750: Price of brain tumor, lymphoma medication has jumped 1,400 percent | FOX6Now.com

From $50, to $750: Price of brain tumor, lymphoma medication has jumped 1,400 percent | FOX6Now.com

MIAMI, Florida — A drug maker is being accused of price gouging. NextSource Biotechnology is under fire after the Wall Street Journal revealed the price of its 40-year-old cancer drug Lomustine has jumped 1,400 percent since 2013. Lomustine treats brain tumors and Hodgkin’s Lymphoma. It’s the only drug of its kind on the market — […]

Investor group pushes big pharma to report links between pricing and executive compensation | Becker’s Hospital Review

Investor group pushes big pharma to report links between pricing and executive compensation | Becker’s Hospital Review

A group of institutional investors, with more than $400 billion of assets, is urging big pharmaceutical manufacturers to begin reporting links between drug pricing strategies and executive compensation, according to Bloomberg. The Interfaith Center on Corporate Responsibility, submitted shareholder proposals at the annual meetings of Abbvie, Amgen, Biogen, Bristol Myers Squibb and Eli Lilly Co. […]

Avion and Acella Pharmaceuticals Provide Statement Related to Avondale Drug Pricing News | PR Newswire

Avion and Acella Pharmaceuticals Provide Statement Related to Avondale Drug Pricing News | PR Newswire

Avion and Acella were made aware of the recent 800 percent price increase for Avondale’s version of niacin, going from $32.46 to $295 per 100 pills.  Avion and Acella pharmaceuticals are led by CEO, Art Deas.  Mr. Deas has confirmed that both companies were unaware of the Avondale pricing activity and that neither company has […]

Big Pharma Is Urged to Report on Links Between Pricing and Pay | Bloomberg

Big Pharma Is Urged to Report on Links Between Pricing and Pay | Bloomberg

Pharmaceutical companies should be required to regularly report whether there’s a link between drug-pricing strategies and executive-compensation plans, according to a shareholder group. The Interfaith Center on Corporate Responsibility, a coalition of institutional investors with more than $400 billion of assets, said in a statement Wednesday that it submitted proposals for inclusion at the 2018 annual […]